Morepen Laboratories Limited has delivered steady financial performance in Q3FY26, reporting consolidated net profit growth of 3.07% year-on-year. The pharmaceutical company's results for the quarter ended December 31, 2025, demonstrate resilient operational execution amid evolving market conditions.

Financial Performance Overview

The company's consolidated financial results show consistent growth across key metrics for Q3FY26:

Income from operations (net) reached ₹48416.10 crores in Q3FY26, marking a 6.93% increase from ₹45278.07 crores in the corresponding quarter of the previous year. Other income contributed ₹380.56 crores compared to ₹533.69 crores in Q3FY25.

Operational Efficiency and Cost Management

Total expenditure for the quarter stood at ₹45254.54 crores, up from ₹42291.17 crores in Q3FY25. The company maintained operational discipline across various cost categories:

Profit before tax reached ₹3542.12 crores in Q3FY26, maintaining consistency with ₹3520.59 crores achieved in Q3FY25. Tax expenses totaled ₹792.57 crores compared to ₹851.74 crores in the previous year quarter.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, consolidated performance showed mixed results:

The company recorded exceptional income of ₹2582.54 crores during the nine-month period, contributing to overall profitability. Total comprehensive income for the nine months reached ₹7895.82 crores.

Corporate Structure and Subsidiaries

Significant changes occurred in the corporate structure during FY26. Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025, following reduction in Morepen Laboratories' shareholding to 19.96% from 80%. Consequently, Dr. Morepen Limited and its step-down subsidiaries Total Care Limited and Quick Med Private Limited are no longer included in consolidated results from that date.

The current subsidiary structure includes wholly-owned subsidiaries Morepen Rx Ltd., Morepen Devices Limited, Morepen Bio Inc. (USA), and Morepen Labs FZCO (UAE), along with majority-owned Morepen Medipath Limited (60%) and Sigmacheck Health Private Limited (60%).

Standalone Results Highlight Core Operations

Standalone financial results for Q3FY26 showed strong performance with net profit of ₹2349.58 crores compared to ₹2268.64 crores in Q3FY25, representing 3.57% growth. Standalone total income reached ₹46150.43 crores, up 13.08% from ₹40812.87 crores in the corresponding previous quarter.

The Board of Directors approved these unaudited financial results in their meeting held on February 10, 2026, following review by the Audit Committee and limited review by statutory auditors.

Morepen laboratories has submitted a compliance report to the National Stock Exchange and BSE Limited regarding the status of physical share transfer re-lodgement requests under SEBI's special window provision. The report, dated January 28, 2026, provides details on transfer requests processed during the initial period of the special window.

SEBI Special Window Compliance

The submission was made in accordance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025. This circular granted a special 6-month window for re-lodgement of physical share transfer requests, running from January 1, 2026 to June 30, 2026. The current report covers the initial period from January 1 to January 6, 2026.

Transfer Request Status Summary

The status report was prepared by MAS Services Limited, the company's Registrar and Share Transfer Agent. The report provides a comprehensive breakdown of transfer request activities during the specified period.

Registrar and Transfer Agent Details

MAS Services Limited, serving as the Registrar to Issue and Share Transfer Agent, confirmed the status as of the reporting period. The company is registered with CIN U74899DL1973PLC006950 and operates from its registered office at T-34, 2nd Floor, Okhla Industrial Area, Phase-II, New Delhi.

Corporate Communication

The report was signed by Vipul Kumar Srivastava, Company Secretary (F-12148), and submitted to both stock exchanges where Morepen Laboratories shares are listed. The company trades on NSE under the symbol MOREPENLAB and on BSE with scrip code 500288.

Company Information

Morepen Laboratories Limited operates with CIN L24231HP1984PLC006028. The company maintains its corporate office at Tower C, DLF Cyber Park, Gurugram, Haryana, while its registered office is located at Morepen Village, Baddi, Himachal Pradesh. This regulatory filing demonstrates the company's commitment to maintaining transparency and compliance with SEBI regulations regarding physical share transfers.